Navigation Links
Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
Date:5/12/2009

WELLESLEY HILLS, Mass., May 12 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that assets of Prospect Therapeutics, Inc. ("Prospect") have been assigned to him for the benefit of Prospect's creditors.

Prospect's lead product candidate, GCS-100, is a carbohydrate molecule designed to inhibit the activity of galectin-3, a protein found in high concentration in a broad range of human cancers and whose over-expression is associated with poor prognosis in cancer patients. It is presently in Phase 2 clinical trials. The intellectual property, regulatory dossier, fixed assets and clinical inventory will be sold at auction on Monday, June 29, 2009 at 12:00 noon.

Persons interested in bidding must sign a Confidentiality Agreement ("CA") obtained from Finn's Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignment for the Benefit of Creditors in the biotech field was Spherics, Inc. and ActivBiotics, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@earthlink.net


'/>"/>
SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Publication of Supplementary Prospectus
2. Pro Football Prospects Training at TEST Sports Clubs(TM) Use SURGEX(TM) as Part of Their Pre-Combine Training Regime
3. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
4. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
5. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
6. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
7. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
8. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
9. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
10. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
11. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... NeoTrident, a leading provider of ... performance management systems for high-consequence industries, announced today that they have entered into ... industry, organizations must pay much more attention to the quality of products than ...
(Date:1/16/2017)... 16, 2017   Valentin A. Pavlov, PhD , ... president and CEO of The Feinstein Institute for ... of how the nervous system regulates the immune system, ... bioelectronic medicine devices to treat disease and injury. ... . The paper examines various studies which ...
(Date:1/13/2017)... Research and Markets has announced the addition ... Forecast to 2021" report to their offering. ... The biosimilars market is expected ... in 2016, at a CAGR of 26.3%. The ... type, and application. Factors such as rising incidence of various diseases, ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... SUCCESS , VTI, Vertebral Technologies, Inc., announces the successful outcome of the ... Since September 2016, VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based medical ...
Breaking Biology Technology:
(Date:12/22/2016)... 2016  As part of its longstanding mission to improve ... company, recently released its latest children,s book, titled ... on the topics of inheritance and variation of traits that ... in elementary school classrooms in the US. ... Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/19/2016)... 19 de diciembre de 2016  Mosaic Biomedicals SL anunció hoy ... de MSC-1, un anticuerpo humanizado que se espera comenzar a utilizar ... múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el primer ... leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos tumores ...
(Date:12/15/2016)... , December 15, 2016 Arvato ... an agreement with NuData Security, an award-winning international ... will enable clients to focus on good customer experience, balancing ... regulation. ... In order to provide a one-stop fraud prevention suite, Arvato ...
Breaking Biology News(10 mins):